Then, survival analysis was made across all genes and the best performing genes were ranked for two cohorts with high clinical relevance: ER positive ERBB2 negative patients who received chemotherapy and basal breast tumors with chemotherapy. This evidence concerns the gene ERBB2 and breast neoplasm.